U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07456085) titled 'Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves' on Jan. 20.
Brief Summary: Warfarin is the standard anticoagulant for patients with mechanical heart valves, yet its use is often complicated by the need for strict INR monitoring, dietary limitations, frequent drug interactions, and a persistent risk of bleeding or thromboembolic events even with careful dosing. These challenges are particularly significant in resource-limited countries such as Pakistan, where many patients have limited access to reliable INR testing. Direct oral anticoagulants such as rivaroxaban offer predictable pharmacokinetics, rapid onset of ac...